Xilio Therapeutics Management
Management criteria checks 1/4
Xilio Therapeutics' CEO is Rene Russo, appointed in May 2019, has a tenure of 5.5 years. total yearly compensation is $3.00M, comprised of 19.9% salary and 80.1% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $262.83K. The average tenure of the management team and the board of directors is 1.4 years and 3.8 years respectively.
Key information
Rene Russo
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 19.9% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$66m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$3m | US$598k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$84m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$2m | US$575k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$85m |
| Jun 30 2022 | n/a | n/a | -US$82m |
| Mar 31 2022 | n/a | n/a | -US$80m |
| Dec 31 2021 | US$5m | US$485k | -US$76m |
| Sep 30 2021 | n/a | n/a | -US$77m |
| Jun 30 2021 | n/a | n/a | -US$75m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$3m | US$450k | -US$55m |
Compensation vs Market: Rene's total compensation ($USD3.00M) is above average for companies of similar size in the US market ($USD656.26K).
Compensation vs Earnings: Rene's compensation has increased whilst the company is unprofitable.
CEO
Rene Russo (49 yo)
5.5yrs
Tenure
US$2,999,910
Compensation
Dr. Rene Russo, BCPS, PharmD., serves as Director at Celsius Therapeutics, Inc. since May 2020. Since May 2019, Dr. Russo has been the Chief Executive Officer and Director of Xilio Therapeutics, Inc., (for...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$3.00m | 0.46% $ 262.8k | |
| Chief Operating Officer | 1.3yrs | US$1.86m | 0% $ 0 | |
| Chief Medical Officer | 1.2yrs | US$932.17k | 0% $ 0 | |
| Senior VP of Finance & Accounting | 1.6yrs | no data | no data | |
| Chief Scientific Officer | 2.3yrs | no data | no data | |
| Chief Development Officer | 1.2yrs | no data | no data |
1.4yrs
Average Tenure
48.5yo
Average Age
Experienced Management: XLO's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$3.00m | 0.46% $ 262.8k | |
| Non-Employee Independent Chairman | 4.3yrs | US$96.77k | 0% $ 0 | |
| Independent Director | 3.9yrs | no data | no data | |
| Independent Director | 3.3yrs | US$76.77k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$78.05k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Board: XLO's board of directors are considered experienced (3.8 years average tenure).